CompletedPhase 4

Evaluation of the Cardioprotective Effect of L-carnitine and Silymarin in Patients Receiving Anthracycline Chemotherapy

Egypt83 participantsStarted 2018-09-10

Plain-language summary

the study aim to protect patients received anthracyclines containing chemotherapy from cardiotoxcity induced by anthracyclines derivatives. by using L-carnitine and Silymarin for protection the heart from anthracyclines toxicities, and in addition its a comparitive study between L-carnitine and Silymarin.

Who can participate

Age range20 Years – 60 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * cancer patients receiving anthracycline chemotherapy in their protocol alone (without any cardioprotective agent), * aged 20-60 and * female patients were included. Exclusion Criteria: * patients with a history of heart failure, arrhythmia, history of cardiac catheterizations or, history of angina, uncontrolled hypertension and uncontrolled diabetes, * patients with impaired liver function tests, * previous anthracycline-containing regimens and any cardiotoxic chemotherapy regimens, * previous history of chest wall irradiation. * Brain metastasis, * pregnant patients and * patients who refused informed consent,

What they're measuring

The use of l-carnitine may be of use in extending the continuous use of anthracycline-containing chemotherapy

Timeframe: from the baseline untill 3 months

Trial details

NCT IDNCT04434404

SponsorHorus University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-08-13

View on ClinicalTrials.gov More Breast Cancer trials